Skip to main content
  • Medicaid Provider Alert: Provider revalidation has begun and those not completing the process risk disenrollment.  Check your account now to learn when your revalidation is due. More information here.
Elizabeth M. Whitehorn, Director

Drugs and Therapeutics (D & T) Committee Meeting Results for: December 2, 2009

Drug Name Review Type Committee Recommendation Prior Approval Status � Final Determination
Tyvaso New Drug Initial Review Require Prior Approval Prior Approval Required
Renvela New Drug Initial Review Require Prior Approval Prior Approval Required
Embeda New Drug Initial Review Require Prior Approval Prior Approval Required
Stelara New Drug Initial Review Require Prior Approval Prior Approval Required
Simponi New Drug Initial Review Require Prior Approval Prior Approval Required
Vivitrol New Drug Initial Review Removed from Agenda Prior Approval Required
Extavia New Drug Initial Review Remove Prior Approval Requirement Prior Approval Requirement Removed
Zenpep New Drug Initial Review Require Prior Approval Prior Approval Required
Lamictal XR New Drug Initial Review Require Prior Approval Prior Approval Required
Lamictal ODT New Drug Initial Review Require Prior Approval Prior Approval Required
Vyvanse New Drug Appeal Remove Prior Approval Requirement Prior Approval Required
Bromfed DM New Drug Appeal Require Prior Approval Prior Approval Required
Savella New Drug Appeal Remove Prior Approval Requirement Prior Approval Required
Nascobal New Drug Appeal Require Prior Approval Prior Approval Required
Saphris New Drug Appeal Remove Prior Approval Requirement Prior Approval Required
Moxatag New Drug Appeal Require Prior Approval Prior Approval Required